A Study of Sigvotatug Vedotin in Advanced Solid Tumors

← catalyst calendar

NCT04389632 · readout in 301 d

Sponsored by Seagen, a wholly owned subsidiary of Pfizer (industry) · PFE — their whole pipeline →.

Phase

Phase 1

Status

Recruiting

Study type

Interventional

Design

Na · None · Treatment

Enrollment

1,006estimated

Sites

158

Countries

France, South Korea, Spain +4

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2020-06-08

actual

When the study began enrolling

Primary completion

2027-06-16

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2029-03-22

estimated

The whole study's end, after follow-up

First posted

2020-05-15

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-07-06

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Carcinoma, Non-Small Cell Lung
Squamous Cell Carcinoma of Head and Neck
HER2 Negative Breast Neoplasms
Esophageal Squamous Cell Carcinoma
Esophageal Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
Ovarian Neoplasms
Cutaneous Squamous Cell Cancer
Exocrine Pancreatic Adenocarcinoma
Urinary Bladder Neoplasms
Uterine Cervical Neoplasms
Stomach Neoplasms

Interventions

Drug: sigvotatug vedotin — also filed as SGN-B6A, PF-08046047
Drug: pembrolizumab — also filed as Keytruda
Drug: cisplatin
Drug: carboplatin

Primary outcomes

what the primary-completion date above is the date OF

Number of participants with adverse events (AEs)

measured Through 30-37 days following last dose of sigvotatug vedotin. For participants receiving pembrolizumab up to 90 days after last dose of pembrolizumab; up to 3 years

Number of patients with laboratory abnormalities

measured Through 30-37 days following last dose of sigvotatug vedotin; up to 3 years

Number of participants with dose-limiting toxicities (DLTs)

measured Through 30-37 days following last dose of sigvotatug vedotin; up to 3 years

Publications

PMID 37619980 — linked by the registry

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed